Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
08:00am, Wednesday, 31'st Jan 2024
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
02:53am, Wednesday, 31'st Jan 2024
Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 02'nd Jan 2024
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology
05:58am, Monday, 11'th Dec 2023
Cabaletta Bio is developing targeted cellular therapies for autoimmune diseases, including systemic lupus erythematous and myositis. Their lead program, CABA-201, is a CD19 chimeric antigen receptor (
Buy Cabaletta Bio's Promising SLE Treatment
02:44am, Sunday, 10'th Dec 2023
Cabaletta Bio is a biotech company with promising CARTA and CAART therapies for autoimmune diseases. Their main research project, CABA-201, targets patients suffering from SLE, opening up a huge marke
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
04:30pm, Tuesday, 28'th Nov 2023
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
03:55pm, Tuesday, 28'th Nov 2023
Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administrat
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
07:00am, Thursday, 09'th Nov 2023
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patien
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
08:00am, Monday, 30'th Oct 2023
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
11:17am, Monday, 09'th Oct 2023
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
10:31am, Monday, 25'th Sep 2023
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
08:00am, Tuesday, 19'th Sep 2023
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi
Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?
04:56am, Tuesday, 19'th Sep 2023
Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than oncolo
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
10:32am, Friday, 08'th Sep 2023
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
